ArticleJournal of clinical laboratory analysis2022
Mettl3 promotes oxLDL-mediated inflammation through activating STAT1 signaling.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- METTL3 Alleviates Liver Abscess by Enhancing Macrophage Efferocytosis via mImmunity, inflammation and disease · 2026Article
- METTL3-mCellular & molecular biology letters · 2026Article
- mFrontiers in immunology · 2026Review
- ADAP-METTL3 modulates the inflammatory responses of macrophages via mCell death & disease · 2025Article
- The Critical Roles of Methyltransferase-Like 3 in Atherosclerosis and Arterial Infarction: Breakthroughs in Mechanism Understanding.Journal of cellular and molecular medicine · 2025Review
- METTL3: a multifunctional regulator in diseases.Molecular and cellular biochemistry · 2025Review
- A comprehensive review of m6 A methylation in coronary heart disease.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Epigenetics of maternal-fetal interface immune microenvironment and placental related pregnancy complications.Frontiers in immunology · 2025Review
- Epitranscriptome: A Novel Regulatory Layer during Atherosclerosis Progression.Current medicinal chemistry · 2025Review
- The role of mFrontiers in immunology · 2025Review
- The YTHDC1-m6A-MEG3 Regulatory Axis in Radiation-Induced Liver Injury: Deciphering Early-Stage Epitranscriptomic Alterations and Molecular Dynamics.Journal of inflammation research · 2025Article
- NAging and disease · 2024Review
- The role of m6A in angiogenesis and vascular diseases.iScience · 2024Review
- Insights into the role of RNA mGenes & diseases · 2024Review
- Transcriptome-wide NBMC genomics · 2023Article
- m6A 'writer' KIAA1429 regulates the proliferation and migration of endothelial cells in atherosclerosis.Molecular biotechnology · 2023Article
- The Epigenetic Regulation of RNA N6-Methyladenosine Methylation in Glycolipid Metabolism.Biomolecules · 2023Review
- Emerging role of METTL3 in inflammatory diseases: mechanisms and therapeutic applications.Frontiers in immunology · 2023Review
- The Mechanism and Role ofJournal of cardiovascular development and disease · 2022Review
- Inhibition of the m6A Methyltransferase METTL3 Attenuates the Inflammatory Response in Fusarium solani-Induced Keratitis via the NF-κB Signaling Pathway.Investigative ophthalmology & visual science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAtherosclerosis (AS) is the main cause of cerebrovascular diseases, and macrophages act important roles during the AS pathological process through regulating inflammation. Modification of the novel N(6)-methyladenine (m6A) RNA is reported to be associated with AS, but its role in AS is largely unknown. The aim of this study was to investigate the role and mechanism of m6A modification in inflammation triggered by oxidized low-density lipoprotein (oxLDL) in macrophages during AS.
methodsRAW264.7 macrophage cells were stimulated with 40 μg/ml ox-LDL, Dot blot, Immunoprecipitation, western blot, Rip and chip experiments were used in our study.
resultsWe found oxLDL stimulation significantly promoted m6A modification level of mRNA in macrophages and knockdown of Methyltransferase-Like Protein 3 (Mettl3) inhibited oxLDL-induced m6A modification and inflammatory response. Mettl3 promoted oxLDL-induced inflammatory response in macrophages through regulating m6A modification of Signal transducer and activator of transcription 1 (STAT1) mRNA, thereby affecting STAT1 expression and activation. Moreover, oxLDL stimulation enhanced the interaction between Mettl3 and STAT1 protein, promoting STAT1 transcriptional regulation of inflammatory factor expression in macrophages eventually.
conclusionsThese results indicate that Mettl3 promotes oxLDL-triggered inflammation through interacting with STAT1 protein and mRNA in RAW264.7 macrophages, suggesting that Mettl3 may be as a potential target for the clinical treatment of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.